Library Subscription: Guest
Critical Reviews™ in Oncogenesis

Published 4 issues per year

ISSN Print: 0893-9675

ISSN Online: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders

Volume 20, Issue 5-6, 2015, pp. 485-508
DOI: 10.1615/CritRevOncog.v20.i5-6.170
Get accessGet access

ABSTRACT

Protein kinases play a critical regulatory role in essentially every aspect of cell biology. Of the 518 known kinases, the most successful class for drug targeting is the receptor tyrosine kinase (RTK) family consisting of 58 distinct and diverse members. RTKs regulate a broad range of cellular functions, including proliferation, differentiation, survival, and apoptosis and have been intensively studied in development and cancer. Targeting of RTKs has resulted in many marketed small molecule and antibody-based drugs in a number of different solid tumors and hematological malignancies, and more recently in inflammatory diseases such as idiopathic pulmonary fibrosis. In this review, we discuss some of the RTKs in cancer in which drugs targeting the ErbB family (EGFR, HER2, and ErbB3) and KIT have had meaningful clinical benefit to cancer patients, RTKs' emerging role in regulating innate immunity, and the potential to explore targeting RTKs outside of oncology.

CITED BY
  1. Lateef Zabeen, Wise Lyn M., Exploitation of receptor tyrosine kinases by viral-encoded growth factors, Growth Factors, 36, 3-4, 2018. Crossref

  2. Dubrovskii Yaroslav, Murashko Ekaterina, Chuprina Olga, Beltyukov Petr, Radilov Andrey, Solovyev Nikolay, Babakov Vladimir, Mass spectrometry based proteomic approach for the screening of butyrylcholinesterase adduct formation with organophosphates, Talanta, 197, 2019. Crossref

  3. Kadivar Ali , Ibrahim Noordin Mohamed , Aditya Arya , Kamalidehghan Behnam , Davoudi Ehsan , Sedghi Reihaneh , Akbari Javar Hamid , Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression, International Journal of Molecular Medicine, 2018. Crossref

  4. Wang Mengli, Du Qiuzheng, Zuo Lihua, Xue Peng, Lan Chao, Sun Zhi, Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo, Current Drug Metabolism, 21, 13, 2020. Crossref

  5. Tang Rong, Langdon Wallace Y., Zhang Jian, Negative regulation of receptor tyrosine kinases by ubiquitination: Key roles of the Cbl family of E3 ubiquitin ligases, Frontiers in Endocrinology, 13, 2022. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain